Plus Therapeutics Reports Positive Interim Updates from Two ReSPECT Clinical Trials at SNMMI Annual Meeting (GlobeNewswire) - Jun 29, 2023 - P1 | N=18 | ReSPECT-LM (NCT05034497) | Sponsor: Plus Therapeutics | "Plus Therapeutics...reported positive interim updates from the...ReSPECT-LM clinical studies evaluating the Company's lead radiotherapeutic, rhenium (186Re) obisbemeda...at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) Annual Meeting....Interim results from 10 patients in the Phase 1 trial show a single treatment with rhenium (186Re) obisbemeda decreased cerebrospinal fluid (CSF) tumor cell count and was well-tolerated in patients with LM....A single rhenium (186Re) obisbemeda administered dose between 6.6 mCi and 26.4 mCi achieved absorbed doses of up to 88.98 Gy to the ventricles and cranial subarachnoid space....An expansion in Cohort 3 is currently enrolling eligible patients. A full update will be provided at the SNO/ASCO CNS Cancer Conference in August 10-12, 2023."
Enrollment status • P1 data • Brain Cancer • CNS Tumor • Oncology • Solid Tumor
|